Parameter
| Biomarker | CA19-9 | Full name | Carbohydrate antigen 19-9 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Carbohydrate antigen 19-9 | Molecular Weight | ~1000 Da | Core Functional Dimensions | Diagnosis, Prognosis |
| Disease | Cholangiocarcinoma (CCA) | Disease Subtypes | / | ||
| Organ | Bile duct/Liver | Test Sample / Technology Platform | Serum (immunoassay, ELISA) | ||
| Pathobiological Mechanisms | It is abnormally elevated in malignant tumors such as cholangiocarcinoma, and may also be elevated in benign biliary diseases such as obstruction and cholangitis. Those with negative Lewis antigen (about 5-10% of the population) do not secrete it | ||||
| Clinical Availability Status | Commonly used in clinic (auxiliary diagnosis); The specificity is limited, so it should be combined with other indicator | ||||
| Notes and Dynamics | It is often used in combination with CEA to monitor treatment response. The false positive rate is more than 50% in biliary obstruction, which limits its diagnostic value | ||||